Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Dec 2017 According to a McKesson Specialty Health and US Oncology Research media release, results from this trial will be presented at the 59th American Society of Hematology Annual Meeting and Exposition (ASH).
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 16 Dec 2016 Status changed from not yet recruiting to recruiting.